Afatinib (Gilotrif)

Indications

  • Breast Cancer (see Breast Cancer, [[Breast Cancer]]): investigational
  • Non-Small Cell Lung Cancer (see Lung Cancer, [[Lung Cancer]]): FDA-approved

Pharmacology

  • Irreversible Covalent Inhibitor of Receptor Tyrosine Kinases
    • Epidermal Growth Factor Receptor (EGFR)
    • erbB-2 (HER2)

Administration

  • XXX

Dose Adjustment

  • Hepatic
  • Renal

Adverse Effects

Dermatologic Adverse Effects

  • Dry Skin: >10% of cases
  • Hand Foot Syndrome (Chemotherapy-Induced Acral Erythema): 1-10% of cases
  • Pruritus (see Pruritus, [[Pruritus]]): >10% of cases
  • Rash/Dermatitis: >10% of cases

Gastrointestinal Adverse Effects

  • Anorexia (see Anorexia, [[Anorexia]]): >10% of cases
  • Cheilitis: 1-10% of cases
  • Diarrhea (see Diarrhea, [[Diarrhea]]): >10% of cases
  • Stomatitis: >10% of cases
  • Taste Changes: 1-10% of cases
  • Transaminitis: 1-10% of cases

Ophthalmologic Adverse Effects

  • Conjunctivitis: 1-10% of cases
  • Dry Eyes: 1-10% of cases
  • Keratitis: 0.1-1% of cases

Otolaryngologic Adverse Effects

  • Epistaxis (see Epistaxis, [[Epistaxis]]): >10% of cases
  • Rhinorrhea/Nasal Congestion (see Rhinorrhea, [[Rhinorrhea]]): 1-10% of cases

Pulmonary Adverse Effects

Renal Adverse Effects

  • Acute Kidney Injury (AKI) (see Acute Kidney Injury, [[Acute Kidney Injury]]): 1-10% of cases
  • Hypokalemia (see Hypokalemia, [[Hypokalemia]]): 1-10% of cases

Other Adverse Effects

  • Cystitis: 1-10% of cases
  • Dehydration: 1-10% of cases
  • Fever (see Fever, [[Fever]]): 1-10% of cases
  • Muscle Spasms: 1-10% of cases
  • Paronychia: >10% of cases

References

  • xxx